Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Rating of “Reduce” from Brokerages

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been given an average rating of “Reduce” by the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $23.00.

Several research analysts have recently issued reports on the company. Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective on the stock. Citigroup boosted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Finally, Bank of America cut their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th.

Integra LifeSciences Trading Up 1.8 %

IART opened at $26.05 on Friday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -289.41, a PEG ratio of 0.83 and a beta of 1.16. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The stock has a fifty day moving average price of $23.32 and a 200-day moving average price of $22.33.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm’s revenue was down .4% on a year-over-year basis. During the same period in the previous year, the company posted $0.76 earnings per share. As a group, equities research analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IART. Principal Financial Group Inc. increased its holdings in shares of Integra LifeSciences by 18.7% during the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock worth $7,294,000 after buying an additional 63,266 shares during the last quarter. Versor Investments LP purchased a new position in Integra LifeSciences in the third quarter worth approximately $612,000. BNP Paribas Financial Markets increased its stake in Integra LifeSciences by 824.5% during the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company’s stock worth $2,031,000 after acquiring an additional 99,685 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Integra LifeSciences in the third quarter valued at $960,000. Finally, State of Alaska Department of Revenue grew its holdings in shares of Integra LifeSciences by 144.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company’s stock worth $2,393,000 after purchasing an additional 77,825 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.